-
1 week ago | 
pf-media.co.uk | Emma Cooper
Sapio Sciences, the science-aware™ lab informatics platform, has announced the promotion of Gordon McCall to Chief Operating Officer (COO). McCall has served as the company’s Chief Financial Officer (CFO) since 2022 and brings a proven track record of leadership, strategic execution, and operational acumen.
-
2 weeks ago | 
pf-media.co.uk | Emma Cooper
The National Institute for Health and Care Excellence (NICE) has recommended a new treatment option for chronic kidney disease, for use in the NHS. Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary immunoglobulin A nephropathy (IgAN), also known as Berger’s disease.
-
3 weeks ago | 
pf-media.co.uk | Emma Cooper
Johnson & Johnson has announced that BALVERSA®▼ (erdafitinib) has been accepted for use within NHS Scotland for the treatment of eligible adults with unresectable or metastatic urothelial cancer (UC) which is harbouring susceptible fibroblast growth factor receptor (FGFR3) genetic alterations, and who have previously received at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
-
3 weeks ago | 
pf-media.co.uk | Emma Cooper
eXmoor Pharma, the integrated cell and gene therapy CDMO, has entered into a strategic partnership with KU Leuven, one of Europe’s leading academic institutions, to support a new cell and gene therapy hub. The collaboration brings together complementary scientific, regulatory and manufacturing capabilities to accelerate innovative cell and gene therapies from bench to first-in-human trials.
-
1 month ago | 
pf-media.co.uk | Emma Cooper
Aspire Pharma Limited, a UK-based specialty niche generics business, has announced the bolstering of its product portfolio through the purchase of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.
-
1 month ago | 
pf-media.co.uk | Emma Cooper
The Medicine and Healthcare products Regulatory Agency (MHRA) has issued Promising Innovative Medicine (PIM) designation to giredestrant, an investigational medicine in development as a single agent and in combination with other anti-cancer therapies for oestrogen receptor (ER) positive breast cancer. Giredestrant is an investigational, next-generation oral selective oestrogen receptor antagonist and degrader (SERD).
-
1 month ago | 
pf-media.co.uk | Emma Cooper
The National Institute for Health and Care Excellence (NICE) has recommended Yselty®▼ (linzagolix) for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. It is expected that this decision will now enable eligible women across England, Wales and Northern Ireland to access this medicine on the NHS.
-
1 month ago | 
pf-media.co.uk | Emma Cooper
The National Institute for Health and Care Excellence (NICE) has officially backed an AI tool for detecting skin cancer, marking a major milestone in the use of AI to free up specialist clinician’s capacity and improve outcomes across the NHS. The outcome formally endorses the autonomous use of the technology to discharge patients with benign skin lesions – supporting NHS organisations already using it in this way and providing a clear signal for wider adoption.
-
1 month ago | 
pf-media.co.uk | Emma Cooper
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Pfizer’s Hympavzi® (marstacimab) for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with:severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, orsevere haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors1.
-
1 month ago | 
pf-media.co.uk | Emma Cooper
Lemer Pax, a worldwide leader in innovative radiation protection solutions, and Synapse Medical, the Diagnostic Imaging division of Uniphar Medtech, are proud to announce a strategic partnership that will expand the distribution of Lemer Pax’s comprehensive portfolio of medical radiation protection products across the UK, effective from 1st April 2025.
